<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Cell-based therapy injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios

dc.contributor.authorde Girolamo, Laura
dc.contributor.authorKon, Elizaveta
dc.contributor.authorLaver, Lior
dc.contributor.authorAndriolo, Luca
dc.contributor.authorBoffa, Angelo
dc.contributor.authorBagge, Jasmin
dc.contributor.authorBarfod, Kristoffer Weisskirchner
dc.contributor.authorBastos, Ricardo
dc.contributor.authorCugat, Ramon
dc.contributor.authorde Caro, Francesca
dc.contributor.authorDi Martino, Alessandro
dc.contributor.authorDrobnic, Matej
dc.contributor.authorEspregueira-Mendes, Joao
dc.contributor.authorIosifidis, Michael
dc.contributor.authorKocaoglu, Baris
dc.contributor.authorMagalon, Jeremy
dc.contributor.authorMangiavini, Laura
dc.contributor.authorMarinescu, Rodica
dc.contributor.authorNehrer, Stefan
dc.contributor.authorOstojic, Marko
dc.contributor.authorSanchez, Mikel
dc.contributor.authorSas, Kristof
dc.contributor.authorSkarpas, George
dc.contributor.authorSlynarski, Konrad
dc.contributor.authorSnow, Martyn
dc.contributor.authorTischer, Thomas
dc.contributor.authorVonk, Lucienne
dc.contributor.authorWinkler, Tobias
dc.contributor.authorFilardo, Giuseppe
dc.date.accessioned2026-11-05T11:09:36Z
dc.date.issued2026
dc.description.abstractPurpose The aim of this consensus was to develop evidence/expert-based patient-focused recommendations on the appropriateness of intra-articular point-of-care (POC) cell-based therapy (CBT) injections in different clinical scenarios of patients with knee osteoarthritis (OA). Methods The RAND/UCLA Appropriateness Method was used by European experts of the European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) and the International Cartilage Regeneration and Joint Preservation Society (ICRS) to reach a consensus and produce recommendations for specific patient categories, combining best available scientific evidence with the collective judgement of a panel of experts. Results A total of 144 scenarios were developed based on five factors: cell source (bone marrow vs. adipose tissue), age (<50 vs. 50-65 vs. 66-80 vs. >80 years), joint involvement (prevalent tibio-femoral vs. patello-femoral), OA level (Kellgren-Lawrence [KL] Grade 0-I vs. II-III vs. IV) and body mass index (BMI) (<18.5 vs. 18.5-35 vs. >35 kg/m(2) ). Following two voting rounds, agreement was reached for all 144 (100%) scenarios: the indication was considered appropriate in 11.8%, inappropriate in 34.7% and uncertain in 53.5%. The parameters with the highest appropriateness were OA Grade II-III (35.4% appropriate scenarios), age <50 years (22.2% appropriate) and BMI 18.5-35 kg/m(2) (20.8% appropriate). The parameters with the highest inappropriateness were age >80 years (88.9% inappropriate), OA grade IV (62.5% inappropriate) and BMI > 35 kg/m(2) (50.0% inappropriate). Conclusions This ESSKA-ICRS expert consensus provides recommendations on the appropriateness of cell-based injectable therapies for knee OA. POC-CBT may be considered, after failure of other non-operative and injectable options, in patients aged <= 65 years with BMI <= 35 kg/m(2) and KL Grade II-III OA. Unlike bone marrow-derived CBT, adipose-derived CBT was also considered appropriate in patients 66-80 years old with BMI 18.5-35 kg/m(2) and KL Grade II-III OA. On the other hand, CBT was considered inappropriate in patients over 80 years old and in those with KL Grade IV OA. These findings may help improve patient selection, although they should not be interpreted as a rigid treatment algorithm but rather as expert-informed guidance for the use of POC-CBT in knee OA.
dc.description.issue8
dc.description.pages3052-3065
dc.description.sponsorshipThe authors would like to thank Luca De Marziani for his support in organizing the consensus. The consensus project was endorsed by the European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) and by the International Cartilage Regeneration and Joint Preservation Society (ICRS).
dc.description.volume34
dc.identifier.doi10.1002/ksa.70487
dc.identifier.issn0942-2056
dc.identifier.issn1433-7347
dc.identifier.urihttps://doi.org/10.1002/ksa.70487
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11640
dc.identifier.wosWOS:001805418200001
dc.language.isoen
dc.publisherWILEY
dc.relation.fundingEuropean Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA)
dc.relation.fundingInternational Cartilage Regeneration and Joint Preservation Society (ICRS)
dc.relation.hasversion10.1002/ksa.70487
dc.relation.ispartofKNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
dc.subjectcell-based therapy
dc.subjectconsensus
dc.subjectinjection
dc.subjectknee
dc.subjectmesenchymal stromal cells
dc.subjectosteoarthritis
dc.subjectRAND/UCLA
dc.subjectARTHROPLASTY
dc.subjectOrthopedics
dc.subjectSport Sciences
dc.subjectSurgery
dc.titleCell-based therapy injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage3065
oaire.citation.issue8
oaire.citation.startPage3052
oaire.citation.volume34
person.identifier.ridJ-9951-2018
person.identifier.ridAAB-8675-2022
person.identifier.ridH-4524-2019
person.identifier.ridLIG-9565-2024
person.identifier.ridW-7954-2018
person.identifier.ridN-4752-2015
person.identifier.ridC-6274-2011
person.identifier.ridC-6863-2019
person.identifier.ridAAY-3288-2021
person.identifier.ridK-6340-2016
person.identifier.ridAAL-6324-2020
person.identifier.ridF-5695-2015

Files

Collections